RIPK1 Promotes Intrinsic and Extrinsic Resistance to Immunotherapy

Cancer Discov. 2022 Jul 6;12(7):1607. doi: 10.1158/2159-8290.CD-RW2022-077.

Abstract

RIPK1 loss enhances immunotherapy by reshaping immune populations and poising tumor cells for killing.

MeSH terms

  • Apoptosis*
  • Humans
  • Immunotherapy
  • Receptor-Interacting Protein Serine-Threonine Kinases* / genetics
  • Receptor-Interacting Protein Serine-Threonine Kinases* / metabolism
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Tumor Necrosis Factor-alpha
  • RIPK1 protein, human
  • Receptor-Interacting Protein Serine-Threonine Kinases